Merck Animal Health Introduces FLOCKSECURE™ Poultry Health Portal

The new web-based platform tool collects and analyzes post-mortem data across farms, complexes and within production companies

RAHWAY, N.J., April 8, 2024 – Merck Animal Health, known as MSD Animal Health outside of
the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA
(NYSE:MRK), today announced the introduction of FLOCKSECURE™ poultry health portal, an
innovative web-based platform solution designed to capture, maintain, distribute and analyze
data from post-mortem sessions.

Designed for the broiler industry, FLOCKSECURE provides a seamless solution to
collect post-mortem data and easily upload it into the web-based portal. The system has the
capability to analyze and compare data across farms, complexes, and within production
companies to track health progress over time and identify trends which provides valuable
insights for data-driven decision-making.

“Merck Animal Health is excited to introduce FLOCKSECURE to our customers,” said
Blayne Mozisek, D.V.M. “This new tool will allow them to compare their flock’s performance
against industry benchmarks using data and insights to make informed decisions to optimize
flock health and performance.”

The tool includes offline data capture capability, allowing users to store data on their
mobile devices and then upload it automatically onto the platform. Future enhancements will
include a mobile application and the addition of nucleic acid-based surveillance data of
important poultry diseases.

FLOCKSECURE is now available through your Merck Animal Health sales or technical
services representative. For more information about Merck Animal Health’s poultry product
portfolio, visit

About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than a century, we’ve been at the forefront of research, bringing
forward medicines, vaccines and innovative health solutions for the world’s most challenging
diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global
animal health business of Merck. Through its commitment to The Science of Healthier Animals ® ,
Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions
and services as well as an extensive suite of connected technology that includes identification,
traceability and monitoring products. Merck Animal Health is dedicated to preserving and
improving the health, well-being and performance of animals and the people who care for them.
It invests extensively in dynamic and comprehensive R&D resources and a modern, global
supply chain. Merck Animal Health is present in more than 50 countries, while its products are
available in some 150 markets. For more information, visit and
connect with us on LinkedIn, Facebook, X (formerly Twitter ) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking

Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products, and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site ( ).

Media Contact:

Kathleen Cuddy
(816) 301-8253